Counter-regulatory renin-angiotensin system in cardiovascular disease

被引：424

作者：

Paz Ocaranza, Maria ^{[1
]}

Riquelme, Jaime A. ^{[2
]}

Garcia, Lorena ^{[2
]}

Jalil, Jorge E. ^{[1
]}

Chiong, Mario ^{[2
]}

Santos, Robson A. S. ^{[3
]}

Lavandero, Sergio ^{[2
,4
,5
]}

机构：

[1] Pontificia Univ Catolica Chile, Fac Med, Adv Ctr Chron Dis ACCDiS, Div Enfermedades Cardiovasc, Santiago, Chile

[2] Univ Chile, Fac Ciencias Quim & Farmaceut, Adv Ctr Chron Dis ACCDiS, Santiago, Chile

[3] Univ Fed Minas Gerais, Inst Biol Sci, Dept Physiol & Biophys, Belo Horizonte, MG, Brazil

[4] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med Cardiol Div, Dallas, TX 75390 USA

[5] Univ Chile, Fac Med, Adv Ctr Chron Dis ACCDiS, Santiago, Chile

来源：

NATURE REVIEWS CARDIOLOGY | 2020年 / 17卷 / 02期

关键词：

D O I：

10.1038/s41569-019-0244-8

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The renin-angiotensin system is an important component of the cardiovascular system. Mounting evidence suggests that the metabolic products of angiotensin I and II initially thought to be biologically inactive - have key roles in cardiovascular physiology and pathophysiology. This non-canonical axis of the renin-angiotensin system consists of angiotensin 1-7, angiotensin 1-9, angiotensin-converting enzyme 2, the type 2 angiotensin II receptor (AT(2)R), the proto-oncogene Mas receptor and the Mas-related G protein-coupled receptor member D. Each of these components has been shown to counteract the effects of the classical reninangiotensin system. This counter-regulatory renin-angiotensin system has a central role in the pathogenesis and development of various cardiovascular diseases and, therefore, represents a potential therapeutic target. In this Review, we provide the latest insights into the complexity and interplay of the components of the non-canonical renin-angiotensin system, and discuss the function and therapeutic potential of targeting this system to treat cardiovascular disease.

引用

页码：116 / 129

页数：14

共 193 条

[1] Angiotensin II type 2 receptor-bradykinin B2 receptor functional heterodimerization [J].